Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infliximab biosimilar - Pfizer

Next Previous
Drug Profile

Infliximab biosimilar - Pfizer

Alternative Names: GP1111; Infliximab-Pfizer; Infliximab-qbtx; IXIFI; PF 06438179; PF 6438179; XILFYA; ZESSLY

Latest Information Update: 07 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Sandoz
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 01 Apr 2025 Launched for Ankylosing spondylitis (In the elderly, In children, In adolescents, In adults) in Canada (IV)
  • 01 Apr 2025 Launched for Crohn's disease (In the elderly, In children, In adolescents, In adults) in Canada (IV)
  • 01 Apr 2025 Launched for Plaque psoriasis (In adults, In children, In adolescents, In the elderly) in Canada (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top